BeOne Medicines AG logo

BeOne Medicines AG(ONC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 91 days
PROFIT SINCE LAST BUY
+37.55% ▲
LAST CLOSE
$416.54
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ONC

11/13/2026: ONC (2-star) has a low Upturn Star Rating. Not recommended to BUY.

BeiGene, Ltd. is a global biotechnology company focused on developing and commercializing oncology medicines. The company has a notable position in the market with its flagship drug, BRUKINSA, and is rapidly expanding its immuno-oncology portfolio through internal R&D. The primary growth opportunity lies in broadening the indications for its approved therapies and establishing its pipeline globally. However, investors must consider risks including intense competition from large pharmaceutical incumbents, persistent operating expenses, and potential regulatory complexities in its US-China operations. This stock may suit growth-oriented investors looking for exposure to the biotechnology sector, though it carries high volatility risks and is not appropriate for those seeking income.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company is in a rapid revenue expansion phase driven by the global launch of flagship oncology products.
Momentum investorStrong fit while signal remains positiveStrong product sales growth and clinical milestones often drive positive price momentum in biotechnology.
Value investorWeak fitThe company is not currently focused on profitability or dividends, making it unsuitable for traditional value strategies.
Dividend investorWeak fitBeiGene does not pay a dividend and is unlikely to do so in the near future.
Low-risk investorWeak fitBiotechnology stocks, particularly those of high-growth companies, carry significant clinical and regulatory risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks are highly sensitive to clinical trial outcomes and regulatory news.
Valuation riskMedium / highHigh valuations often rely on aggressive future growth assumptions.
Competition risk (oncology incumbents)HighCompeting with major pharma giants requires constant, costly innovation.
Business qualityMediumWhile R&D capabilities are strong, the company is still building long-term franchise stability.
Dividend incomeLow / noneThere is no dividend income for investors.
Execution riskMedium / highSuccessfully managing a global, multi-jurisdictional R&D and commercial machine is complex.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 47.58B USD
Price to earnings Ratio 53.4
1Y Target Price 469.23
Price to earnings Ratio 53.4
1Y Target Price 469.23
Volume (30-day avg) 428.8K shares
Beta 0.63
52 Weeks Range 253.95 - 424.73
Updated Date 11/14/2026
52 Weeks Range 253.95 - 424.73
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 7.8

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -14.47%
Avg. Invested days 41
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ONC receives a 4-star rating, supported by solid unit economics, solid company fundamentals, solid quantitative characteristics, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ONC has solid overall fundamentals (4 stars), with solid financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+144.5%) and strong cash generation (FCF margin 17.6%) are partially offset by soft profitability (net margin 5.4%).

Financial Health Rating

★★★★★
ONC's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 53.8%). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ONC's strongest growth driver at +240.6% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+40.2%, strong) and earnings growth (+144.5%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 34.6% and approximately 77.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 17.47% supports management-shareholder alignment.

Top 5 Institutional Investors

Baker Bros Advisors LP 7.71%
PRIMECAP Management Company 4.38%
Capital Research & Mgmt Co - Division 3 3.69%
FMR Inc 2.17%
Capital World Investors 1.97%

Unit Economics (Per $1K Revenue)

★★★★★
ONC generates approximately $875 of gross profit, $84 of operating income, and $176 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and strong cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 31.17%

Quantitative Style Profile

★★★★★
ONC has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology PharmaceuticalsGlobal sales of BRUKINSA, TEVIMBRA, and various in-licensed or proprietary products.The company makes money by selling advanced cancer drugs that doctors prescribe globally.
Geography: ChinaSignificant sales of both internally developed and licensed/distributed therapies in the Chinese market.A significant portion of the company's revenue and established market presence is based in China.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When Before Market
Estimate 2.34
Actual 3.64

Profitability

Profit Margin 13.86%
Operating Margin (TTM) 17.84%

Management Effectiveness

Return on Assets (TTM) 8.42%
Return on Equity (TTM) 18.4%

Valuation

Trailing PE 53.4
Forward PE 36.5
Enterprise Value 43.82B
Price to Sales(TTM) 7.2
Enterprise Value 43.82B
Price to Sales(TTM) 7.2
Enterprise Value to Revenue 6.63
Enterprise Value to EBITDA 30.18
Shares Outstanding 105.38M
Shares Floating 81.48M
Shares Outstanding 105.38M
Shares Floating 81.48M
Percent Insiders 17.47
Percent Institutions 34.6

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.